Skip to main content
Fig. 2 | AIDS Research and Therapy

Fig. 2

From: Effects of pitavastatin on atherosclerotic-associated inflammatory biomarkers in people living with HIV with dyslipidemia and receiving ritonavir-boosted atazanavir: a randomized, double-blind, crossover study

Fig. 2

Inflammatory markers that revealed significant difference of changes from baseline to week 12 of pitavastatin vs. placebo in PLHIV receiving ritonavir-boosted atazanavir; (A) basic FGF, (B) HLA-DR+CD38-CD4+ T cells, (C) PD-1+CD4+ T cells. Y axis shows median change from the baseline

Back to article page

AIDS Research and Therapy

ISSN: 1742-6405

Contact us